small molecule

RAYALDEE

CALCIFEDIOL

Loss of exclusivityMarch 2034latest FDA-listed patent expiry
CompanyEirGen PharmaView the full company profile on CliffBio

Drug detail

Brand nameRAYALDEE
Active ingredientCALCIFEDIOL
Strength0.03MG
Dosage formCAPSULE, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJune 2016
Marketing statusRX

Listed patents

PatentExpiresType
9861644March 2034product
11253528March 2034product
10300078March 2034product
10357502March 2034product
11801253September 2030product
8426391August 2028use U-1872
8361488July 2028product
8778373April 2028use U-1873
9408858April 2028use U-1888
9925147April 2028product
8207149April 2028use U-1871
9498486April 2028use U-3814
11154509April 2028use U-3815
10213442February 2027product
9943530February 2027use U-2274
8906410February 2027product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

RAYALDEE patent cliff — loss of exclusivity March 2034 | CliffBio